# Tesamorelin: research overview > Tesamorelin research overview — Metabolic & Weight research peptides — Metabolic & Weight research peptides: tesamorelin evidence on visceral fat, liver fat, lean mass, GH–IGF-1 signaling, population limits, and safety. **LEAD FILE / BODY COMPOSITION** Visceral fat is not scale weight. Tesamorelin’s file is built around that distinction. ## Start here Tesamorelin is a synthetic analogue of growth hormone-releasing hormone, or GHRH. It prompts the pituitary gland to release the body’s own growth hormone in pulses. That signal raises IGF-1 and can increase fat breakdown, especially in visceral fat around internal organs. This is the lead file because it separates body composition from body weight. Randomized trials in adults with HIV-associated lipodystrophy measured visceral fat, trunk fat, liver fat, and lean mass. A recent pooled analysis found improvement across those measures [6]. The evidence is human and controlled. Its population is narrow. Tesamorelin is approved for excess abdominal fat in adults with HIV-associated lipodystrophy [7]. The trials do not establish routine use for general obesity, aging, or athletic performance. Visceral fat can return after treatment stops [10]. The GH–IGF-1 pathway also raises safety and eligibility questions that a scale cannot capture. ## What it is Tesamorelin is a synthetic peptide based on the full human GHRH sequence. An N-terminal modification makes it more resistant to enzymatic cleavage than native GHRH. It is supplied clinically as tesamorelin acetate. The distinction between GHRH stimulation and direct growth-hormone administration matters. Tesamorelin acts at the pituitary. It amplifies endogenous, pulsatile growth-hormone release rather than replacing the hormone from outside the body. The downstream pathway still includes IGF-1 and lipolysis, but the input retains part of the body’s native rhythm. The United States approval dates to 2010 and is specific: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy [7]. The approved indication is not general weight management. The pivotal research population had metabolic and body-composition changes associated with HIV treatment. That context follows every efficacy claim on this page. ## How it works Tesamorelin binds the GHRH receptor on somatotroph cells in the anterior pituitary. Receptor activation triggers a cyclic-AMP signaling cascade. Growth hormone is then synthesized and released in pulses. Growth hormone stimulates hepatic IGF-1 production, and the combined axis promotes lipolysis. The primary body-composition interest is visceral adipose tissue. Visceral fat sits within the abdominal cavity and differs from subcutaneous fat beneath the skin. Trials measured it with imaging rather than relying on waist appearance or total weight. Liver fat and trunk fat provide additional tissue-specific measures. Lean body mass adds a counterweight: fat reduction and tissue preservation can be examined together. This pathway is metabolically active beyond fat. It can affect glucose handling, fluid balance, connective tissues, and growth signaling. That breadth is why the mechanism cannot be reduced to “belly fat.” It also explains why active malignancy, glucose disturbance, and persistently high IGF-1 are central clinical concerns in the wider safety frame. ## What the research shows A 2026 meta-analysis pooled **five randomized controlled trials** in HIV-associated lipodystrophy. Tesamorelin reduced visceral adipose tissue by a mean **27.71 square centimeters**, trunk fat by **1.18 kilograms**, and hepatic fat fraction by **4.28 percentage points**. Lean body mass increased by a mean **1.42 kilograms** [6]. The pattern is more informative than a total-weight figure: several tissue compartments moved in different directions. A smaller randomized trial followed **50 adults for six months**. The treatment effect was **−42 square centimeters** for visceral fat and a net **−2.9 percentage points** for hepatic fat [8]. A larger Phase 3 trial in **412 adults over 26 weeks** found visceral fat declined **15.2%** while placebo rose **5.0%**; triglycerides also fell in the tesamorelin group [11]. Durability is limited. In a **52-week** program, visceral-fat reduction remained **18% below baseline**, but visceral fat reaccumulated after discontinuation [10]. A short study in **13 healthy men** showed higher overnight growth hormone and IGF-1 without a significant change in measured insulin sensitivity during that brief period [9]. None of these trials proves broad efficacy for general obesity. ## Reported effects, cautions & safety The composed corpus contains no real-world signal set for tesamorelin. No community effects are presented as evidence here. The clinical file is more useful. The pooled randomized-trial analysis reported the body-composition changes without serious adverse events in the included studies [6]. The NIH LiverTox monograph rates tesamorelin as an unlikely cause of clinically apparent liver injury and reports no attributable liver-injury cases in its review [7]. Those findings do not settle long-term safety across unstudied populations. The axis itself sets the main cautions. Tesamorelin raises IGF-1. Active malignancy is a labeled contraindication, and long-term oncologic data remain limited. Glucose can be perturbed in susceptible people even though selected trials did not show clinically significant average change [9][10]. Visceral fat can return when the intervention stops [10]. In sport, tesamorelin sits among prohibited growth-hormone-axis agents, and a review describes uncertain safety and product-quality concerns around investigational peptide use [12]. No use instructions belong in this digest. ## Where it fits in metabolic function Tesamorelin is the body-composition file. Its central measures are visceral fat, liver fat, trunk fat, and lean mass. This makes it unusually aligned with a functional-metabolic frame. The pooled result of lower fat compartments alongside higher lean body mass is the clearest example on this site of why scale weight alone is incomplete [6]. The boundary is strict. Most decisive trials involved adults with HIV-associated lipodystrophy. The evidence cannot be generalized to routine weight loss, longevity, or performance. Approval is tied to that same narrow clinical context [7]. Within the three-way comparison, tesamorelin answers a tissue-distribution question. Semaglutide answers appetite, weight, and clinical-event questions. MOTS-c raises early mechanistic questions about muscle, cellular stress, and energy signaling. They do not substitute for one another. Their outcome sets barely overlap. --- An independent metabolic-function ledger: literature in, measured claims out, no clinical direction.